Table 1.
Parameter | No. |
---|---|
Sex | |
Male | 22 |
Female | 15 |
Median age, years | 58 |
Range | 27-77 |
ECOG performance status | |
0 | 20 |
1 | 17 |
Tumor biopsy sites | |
Liver | 15 |
Abdominal wall | 9 |
Rectum/vaginal wall | 4 |
Scalp | 2 |
Lymph node | 5 |
Prior lines of treatment | |
2-3 | 18 (51%) |
≥4 | 17 (49%) |
Prior treatment | |
Bevacizumab | 15 (43%) |
Cetuximab | 15 (43%) |
Baseline organ function | |
AST (U/L) | 34.6 ± 22.4 |
ALT (U/L) | 23.5 ± 10.9 |
Total bilirubin (μmol/L) | 10.1 ± 5.8 |
Creatinine (μmol/L) | 66.9 ± 27.0 |
37 patients screened; 35 commenced therapy, 2 failed screening.
8 patients did not complete cycle 2 for tumour biopsy and evaluation of response.
11 patients did not have second biopsy.